What Recent Innovations and News Does Johnson & Johnson Highlight?

Johnson & Johnson's corporate site (jnj.com) currently spotlights a mix of business updates and science stories: a third-quarter 2026 earnings breakdown, the naming of ICOTYDE® (icotrokinra) to Time's Best Inventions of 2026 list, and behind-the-scenes pieces on its OTTAVA™ robotic surgical system and on manufacturing CAR-T cell therapy for multiple myeloma. The pattern is worth noting if you're tracking the company: the "Latest news" and "Innovation" sections pair financial results with product-level science explainers, so you can read them either as an investor update or as a plain-language look at where the pipeline is heading.

What the news section covers

The site's news items fall into a few recognizable types:

• Earnings recaps. An October 13, 2026 item offers an infographic breakdown of the third-quarter 2026 earnings report, with highlights split between the Innovative Medicine and MedTech businesses.
• Awards and recognition. An October 15, 2026 item notes that ICOTYDE® (icotrokinra) was named to Time's Best Inventions of 2026 list. The site describes it as a first-of-its-kind targeted oral peptide therapy for moderate to severe plaque psoriasis, recognized for originality, ambition, and impact.
• Product and platform deep dives. Separate items cover the development of the OTTAVA™ Robotic Surgical System and the science behind targeted oral peptides.

If you only want the business picture, the earnings infographic is the fastest read. If you want to understand the science behind a headline, the peptide and CAR-T pieces go deeper.

The innovation stories, briefly

ICOTYDE (icotrokinra) and oral peptides

The award item and the "science behind targeted oral peptides" piece are complementary. The first tells you what was recognized; the second explains the underlying problem the therapy addresses — how to deliver peptide therapies orally and hit their target more precisely, a challenge the site says has long frustrated drug developers. Read together, they give a non-specialist a reasonable grasp of why an oral peptide for psoriasis counts as an innovation rather than just another approval.

CAR-T manufacturing and delivery

A September 25, 2026 item goes behind the scenes on manufacturing and delivering CAR-T cell therapy for multiple myeloma. It frames the process as turning a patient's own cells into a targeted treatment, and quotes Jessica Torfs, director of Global CAR-T Supply Chain, on what delivering this personalized therapy involves. This is the most operations-focused piece in the current lineup — useful if your interest is in supply chain and personalized medicine rather than discovery science.

OTTAVA robotic surgery

The OTTAVA™ Robotic Surgical System item sits under the innovation coverage and is presented as a development story rather than a launch announcement. The site's MedTech section frames the broader portfolio around "smarter, less invasive, more personalized treatments," with cardiovascular, orthopaedics, surgery, and vision as the healthcare areas.

How the pieces map to the two business segments

The mapping is a useful filter: if a headline interests you, check which segment it belongs to before reading further, since the science and the commercial context differ sharply between the two.

What to do with this

• If you're following the company as an investment-adjacent reader, start with the Q3 2026 earnings infographic, then use the innovation items to see which programs sit behind the segment highlights. Note that the site presents results and recognition, not guidance or forecasts.
• If you're a student, researcher, or curious reader, the peptide and CAR-T explainers are the most substantive; they describe mechanisms and manufacturing realities rather than marketing claims.
• If you're job-hunting, the site's careers section links to current openings and hiring programs, which is a separate track from the news content.

One caveat: the site is a corporate communications channel, so treat the framing of "first-of-its-kind" and award language as the company's own description. For independent verification of trial data or regulatory status, cross-check with regulatory filings or peer-reviewed sources rather than the corporate page alone.